What is claimed is:

1. A compound selected from the group of compounds represented by formula (I):

Formula I

wherein:

5

10

15

20

A is $-(CR_2)_n$ - where n is 1, 2, or 3 and R is independently hydrogen or alkyl;

B is aryl or heteroaryl;

X and Y are, independently, CH or nitrogen;

 R^1 is alkyl, alkenyl, cyanoalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaralkyl, heterocyclylalkyl, heteroalkyl or alkylcarbonylalkyl;

 R^2 is alkyl, alkenyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, alkoxycarbonylalkyl, or $NR^{13}R^{14}$ wherein:

R¹³ is hydrogen or alkyl;

R¹⁴ is hydrogen, alkyl, alkenyl, acyl, haloalkyl, cycloalkyl, cycloalkyl, cycloalkyl, aralkyl, hydroxyalkyl, alkoxyalkyl, carboxyalkyl, alkoxycarbonylalkyl, or aminoalkyl;

R³ is hydrogen, alkyl, halo, nitro, cyano, hydroxy, alkoxy; and prodrugs, individual isomers, mixtures of isomers, and pharmaceutically acceptable salts thereof.

2. The compound of Claim 1, wherein:

R³ is hydrogen; and

X and Y are both CH.

- 3. The compound of Claim 2 wherein B is aryl.
- 4. The compound of Claim 3 wherein B is optionally substituted phenyl.

- 5. The compound of Claim 4 wherein R¹ is alkyl, cycloalkyl, cycloalkyl-alkyl, heterocyclyl, heterocyclylalkyl or heteroalkyl.
- 6. The compound of Claim 5 wherein R¹ is heteroalkyl.

10

- 7. The compound of Claim 6 wherein R¹ is alkylsulfonylalkyl.
- 8. The compound of Claim 7 wherein R^2 is alkyl.

15

- 9. The compound of Claim 8 wherein A is $-(CH_2)$ -.
 - 10. The compound of Claim 7 wherein R² is NR¹³R¹⁴ wherein R¹³ and R¹⁴ are hydrogen.
- 11. The compound of Claim 10 wherein A is $-(CH_2)$ -.

20

- 12. The compound of Claim 2 wherein B is heteroaryl.
- 13. The compound of Claim 12 wherein R¹ is alkyl, cycloalkyl, cycloalkyl-alkyl, heterocyclyl, heterocyclylalkyl or heteroalkyl.

25

- 14. The compound of Claim 13 wherein R¹ is heteroalkyl.
- 15. The compound of Claim 14 wherein R¹ is alkylsulfonylalkyl.
- 30 16. The compound of Claim 15 wherein \mathbb{R}^2 is alkyl.

PERIESR:112720v2 70 R0070B-REG

20

5

- 17. The compound of Claim 16 wherein A is $-(CH_2)$ -.
- 18. The compound of Claim 15 wherein R^2 is $NR^{13}R^{14}$ wherein R^{13} and R^{14} are hydrogen.
- 19. The compound of Claim 18 wherein A is $-(CH_2)$ -.
- 20. The compound of Claim 1, wherein: R³ is hydrogen; and
- one of X and Y is N.
 - 21. The compound of Claim 20 wherein B is aryl.
 - 22. The compound of Claim 21 wherein B is optionally substituted phenyl.
 - 23. The compound of Claim 22 wherein R¹ is alkyl, cycloalkyl, cycloalkyl-alkyl, heterocyclyl, heterocyclylalkyl or heteroalkyl.
 - 24. The compound of Claim 23 wherein \mathbb{R}^1 is heteroalkyl.
 - 25. The compound of Claim 24 wherein R¹ is alkylsulfonylalkyl.
 - 26. The compound of Claim 25 wherein R² is alkyl.
- 25 27. The compound of Claim 26 wherein A is –(CH₂)-.
 - 28. The compound of Claim 25 wherein R^2 is $NR^{13}R^{14}$ wherein R^{13} and R^{14} are hydrogen.
 - 29. The compound of Claim 28 wherein A is $-(CH_2)$ -.

30

PERIESR:112720v2 71 R0070B-REG

20

5

- 30. The compound of Claim 20 wherein B is heteroaryl.
- 31. The compound of Claim 30 wherein R¹ is alkyl, cycloalkyl, cycloalkyl-alkyl, heterocyclyl, heterocyclylalkyl or heteroalkyl.
- 32. The compound of Claim 31 wherein R^1 is heteroalkyl.
- 33. The compound of Claim 32 wherein R¹ is alkylsulfonylalkyl.
- 10 34. The compound of Claim 33 wherein \mathbb{R}^2 is alkyl.
 - 35. The compound of Claim 34 wherein A is –(CH₂)-.
 - 36. The compound of Claim 33 wherein R^2 is $NR^{13}R^{14}$ wherein R^{13} and R^{14} are hydrogen.
 - 37. The compound of Claim 36 wherein A is $-(CH_2)$ -.
 - 38. The compound of Claim 1 wherein:

R¹ is alkylsulfonylalkyl;

B is aryl; and

X and Y are CH.

- 39. The compound of Claim 38, wherein R^2 is alkyl.
- 25 40. The compound of Claim 39, wherein A is $-(CH_2)$ -.
 - 41. The compound of Claim 38, wherein R^2 is NH_2 .
 - 42. The compound of Claim 41, wherein A is $-(CH_2)$ -.

5

- 43. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 and a pharmaceutically acceptable excipient.
- 44. A method of treatment of a disease in a mammal treatable by administration of a prostaglandin G/H synthase inhibitor, comprising administration to the mammal a therapeutically effective amount of a compound of Claim 1.
 - 45. The method of Claim 44, wherein the disease is an inflammatory disease.
- 10 46. The method of Claim 45, wherein the inflammatory disease is selected from myositis, synovitis, arthritis (rheumatoid arthritis and osteoarthritis), gout, ankylosing spondylitis and bursitis.
 - 47. The method of Claim 44, wherein the disease is Alzheimer's disease.
 - 48. The method of Claim 44, wherein the disease is an autoimmune disease.
 - 49. The method of Claim 48, wherein the autoimmune disease is selected from systemic lupus erythematosus and type I diabetes.

* * * * *

25

20